SCHEMBL679359

SCHEMBL679359

O=C(O)Nc1ccc(-c2cc3c(cnn3C3CCCCO3)cc2Oc2ccc([N+](=O)[O-])cc2F)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
MAPT P10636 6/20 0.36
MAPK1 P28482 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
HSPB1 P04792 2/20 0.34
EGFR P00533 1/20 0.34
HTT P42858 1/20 0.33
PIK3CD O00329 1/20 0.33
SCN9A Q15858 1/20 0.32
GAA P10253 1/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
NR1H4 Q96RI1 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679358 1.00 RXRA (0.41) RXRARXRBRXRGMAPTMAPK1
SCHEMBL680965 0.90 RXRA (0.40) RXRARXRBRXRGMAPTMAPK1
SCHEMBL680086 0.88 RXRA (0.43) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL680051 0.86 RXRA (0.42) RXRARXRBRXRGMAPTMAPK1
SCHEMBL679898 0.86 RXRA (0.38) RXRARXRBRXRGMAPTMAPK1
SCHEMBL680764 0.85 RXRA (0.40) RXRARXRBRXRGMAPTMAPK1
SCHEMBL680423 0.85 EGFR (0.39) RXRARXRBRXRGMAPTMAPK1
SCHEMBL679314 0.85 RXRA (0.38) RXRARXRBRXRGMAPTMAPK1
SCHEMBL680020 0.85 EGFR (0.39) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL680923 0.84 CYP11B1 (0.40) RXRARXRBRXRGMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC RXRA 4592/4885RXRB 4066/4885RXRG 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.